Transthyretin amyloid cardiomyopathy (ATTR-CM) is a chronic condition associated with progressive heart failure. In this touchCARDIO interview, we speak with Professor Marianna Fontana (National Amyloidosis Centre, University College London, Royal Free Campus, London, UK) to discuss the pathogenesis, prognosis and the unmet needs in the treatment of ATTR-CM.
The abstract entitled ‘NNC60190001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTRCM): rationale and study design of a phase 2, randomized, placebo controlled trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- Could you give us a brief overview of transthyretin amyloid cardiomyopathy (ATTR-CM), its pathogenesis and prognosis? (0:24)
- What are unmet needs in the treatment of ATTR-CM? (2:02)
Disclosures: Marianna Fontana is on the advisory board and a consultant for Alexion, Alnylam, Caelum, Intellia, Ionis, Jannsen, Novo Nordisk and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
